Loading company…
Reapplix develops wound care treatments, including a blood-derived patch for diabetic foot ulcers.
Reapplix develops treatments for chronic wounds, particularly diabetic foot ulcers. Its 3C Patch System uses a patient's blood components to create a patch applied to the wound. Founded in 2008, the company is based in Denmark and raised DKK 150.000 mn across funding rounds, most recently in November 2021 from Lauxera Capital Partners, MK Ventures, North-East Venture, Novo Holdings, and Vaekstfonden.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in